Company intelligence / Profile preview

Lumiris Spectral Solutions

Barcelona, Catalonia, Spainlinkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lumiris has developed a patented, AI-driven hyperspectral imaging medical device to non-invasively assess embryo metabolism, aiming to help IVF specialists select embryos with higher implantation potential. This approach seeks to reduce time-to-pregnancy and unsuccessful IVF cycles. As of mid-2025, the company is preparing for further development and regulatory clearance in both the EU and US markets; no clinical trial results are published yet[1][2][3].

Therapeutic areas: Women's Health
Modalities: Device (medical device for embryo selection)Non-pharmacological therapy (embryo assessment tool)
Industry: Medical Imaging

Beyond the preview

Go deeper on Lumiris Spectral Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumiris Spectral Solutions.

Explore the full profile